At the same time, our results suggest that other targets within the UPR, such as the IRE1α pathway and its downstream targets XBP1 and ASK1, may be better candidates for ALS therapies based on existing evidence. This evidence concerns the gene XBP1 and amyotrophic lateral sclerosis.